

FOR ANIMAL TREATMENT ONLY

EIMERIAVAX 4m

Active Constituents: This vaccine contains viable oocysts of *Eimeria acervulina* Strain RA, *E. maxima* Strain MCK₊₁₀, *E. necatrix* Strain mednec₃₊₈ and *E. tenella* Strain Rt₃₊₁₅ suspended in phosphate buffered saline (PBS). Each dose comprises a minimum of *E. acervulina* 50 oocysts, *E. maxima* 100 oocysts, *E. necatrix* 100 oocysts and *E. tenella* 150 oocysts, with a minimum predicted titre of 1.6×10^4 oocysts per mL at the end of the shelf-life.

Statement of Claims: Live oocyst preparation to aid in the control of the four major species of *Eimeria* that cause Coccidiosis in breeders, broilers and layer chickens in Australia.

1000 Doses

Contents: 1000 doses in a plastic bottle. The *Eimeria* oocysts are supplied as a suspension of oocysts in 25 mL of PBS. Suspensions are contained within a single capped bottle supplied with detachable eyedropper application nozzles. Product is accessed by removing the top foil cap and bung, and inserting the dropper applicator. Eye-drop applicators are enclosed with the vaccine.

READ DIRECTIONS CAREFULLY

DIRECTIONS FOR USE

Contraindications:

- This product is contraindicated for vaccinating unhealthy birds.

Precautions:

- Avoid using in-feed or water anticoccidial medications at or soon after the time of vaccination, unless controlling clinical coccidiosis.
- Avoid vaccinating with EIMERIAVAX 4m unless birds are protected from exposure to litter from the previous batch for up to 14 days post-vaccination.
- Avoid using EIMERIAVAX 4m as a diluent for other medications or treatments.
- This product is not sterile.
- Avoid using in birds in lay.
- Avoid administration of sulfa drugs immediately following vaccination with EIMERIAVAX 4m as this will delay oocyst output and impair immune response.

Dosage And Administration:

USE ALL PRODUCT WITHIN 24 HOURS OF OPENING. Birds from day-old can be vaccinated with EIMERIAVAX 4m. With individual bird administration, it is essential for each bird to receive a full dose. A second dose should be administered if the first is not fully absorbed by the eye. It is recommended that all birds be vaccinated prior to 18 weeks of age. The most appropriate age to vaccinate may be determined from knowledge of the challenge conditions applicable to the flocks concerned. The effect of EIMERIAVAX 4m vaccination during lay has not been assessed.

Method Of Vaccination:

Preparation of vaccine for use and general instructions:

- Prior to use gently shake vials to fully resuspend all oocysts.
- Remove the cap and insert the eye-dropper tip. Hold each bird with its head tilted to one side.
- Invert the dropper bottle allowing a single drop to form at the tip and fall freely into the open eye, gently flooding it. The drop (before release) and tip should NOT touch the eye surface.

- Allow the bird to blink before releasing it.
- Administer a second drop if the bird did not receive a full dose.
- It is recommended that from 5 days post-vaccination, birds be spread over as large a shed floor area as possible. **Birds housed in cages:** These birds should be vaccinated a minimum of 14 days before being placed onto litter or into slat sheds.
- **Birds reared on litter:** These birds can be vaccinated from day-old. Anticoccidial medication is never recommended unless clinical coccidiosis from wild field strains is affecting bird performance. In these instances manufacturers recommendations for the medication program are to be followed.
- If depression associated with vaccination is noted, light intensity should be increased and/or extended and extra feed provided.
- Monitor birds carefully for 4 weeks post-vaccination. Some lesions can be expected. Lesions can be associated with an immune response and should not be used as the sole criterion for assessing efficacy.
- Investigate all suspect coccidiosis lesions as this vaccine does not protect against *Eimeria* species that are not represented in the vaccine. Monitor gross lesions scores for 4 weeks post-vaccination.

Duration of immunity: An effective immune response can be expected for at least 18 weeks post-vaccination. Continuing exposure to oocysts in the environment is essential and provides ongoing stimulus to the immune system. Under these conditions, a protective immune response beyond 18 weeks of age can be expected. When birds are removed from the source of vaccine oocysts, such as when they are transferred between facilities, immunity may wane due to reduced exposure to cycling oocysts. As a result, birds may subsequently become susceptible to field infections from *Eimeria* species represented in the vaccine.

Product bioburden: EIMERIAVAX 4m is not a sterile product. Oocysts for use in EIMERIAVAX 4m are extracted from the faeces of inoculated SPF birds. While the SPF birds are certified free from a specified range of bacterial and fungal pathogens, the oocyst cultures are released for final product manufacture only when specified bioburden limits are satisfied. Users must be aware the origin of the oocysts and the nature of the manufacturing process cannot guarantee EIMERIAVAX 4m is free from all known bacterial and fungal poultry pathogens.

WITHHOLDING PERIODS: NIL

USER SAFETY INFORMATION:

Accidental contact of EIMERIAVAX 4m with eyes or mouth may cause irritation. Eyes should be rinsed immediately and medical advice sought. The mouth should be rinsed two or three times with a mouth gargle.

Additional information is available on the product Material Safety Data Sheet.

FIRST AID:

If poisoning occurs, contact a Doctor or Poisons Information Centre on 13 11 26.

DISPOSAL:

Discard unused vaccine and empty vaccine bottles into a disinfectant solution (e.g. chlorine based bleach). Dispose of any such inactivated, unused vaccine and empty containers by wrapping in paper and putting in garbage. In cases of spillage, soak up the liquid with an absorbent sponge or cloth and incinerate. Treat the surface with a disinfectant solution (e.g. chlorine based bleach).

CAUTION:

The capability of this vaccine to produce satisfactory results depends upon many factors including, but not limited to, conditions of storage and handling by the user, administration of the vaccine, health and responsiveness of individual birds and degree of field exposure. Therefore, directions for use should be followed carefully.

CONTACT DETAILS:

BIOPROPERTIES Pty Ltd
ACN 007 303 728
36 Charter Street
Ringwood
Victoria 3134, Australia
PH: 03 9876 0567 FAX: 03 9876 0556

BIOPROPERTIES Pty Ltd
Eimeria Pty Ltd



STORAGE INSTRUCTIONS:

Product should be stored between 2°C and 8°C (Refrigerate. Do not freeze) until required.
Product should be used by the expiry date.

WARRANTY AND DISCLAIMER

BIOPROPERTIES Pty Ltd manufactures, markets and sells EIMERIAVAX 4m on behalf of Eimeria Pty Ltd. EIMERIAVAX 4m has been tested and meets safety and potency standards according to the Standards required by APVMA. BIOPROPERTIES Pty Ltd and Eimeria Pty Ltd accept no responsibility for events arising from the misuse or mishandling of the product. BIOPROPERTIES Pty Ltd and Eimeria Pty Ltd give no warranty (express or implied) with respect to the product, including without limitation any warranty as to completeness, merchantability or fitness for a particular purpose. Under no circumstances shall BIOPROPERTIES Pty Ltd or Eimeria Pty Ltd be liable for indirect, special, consequential or punitive damages.

APVMA No. 54495/ 0105

Code/Version No: LFT-E4M (4)